Genentech, Inc.

Smithkline Beecham Corporation

Antabio Sas

Mitsubishi Tanabe Pharma Corporation

Almac Discovery Limited

F. Hoffmann-La Roche Ag

Richard Leonard Elliott

Robert Andrew Heald

Steven T Staben

Emily J Hanan

Toby Jonathan Blench

Marie-Gabrielle Braun

Calum Macleod

Eileen Mary Seward

Thomas David Pallin

Timothy Heffron

David Edward Clark

David Thomas Davies

Simon Leiris

Nicolas Sprynski

Martin Everett

Andrew Peter Cridland

Lilha Beyria

Bryan K Chan

BinQing Wei

Colin Andrew Leach

Emanuela Gancia

Calum MacLeod

Michael Lainchbury

Timothy Harrison

Robert John Ife

Stephen Colin Price

Daniel P Sutherlin

Andrew Madin

Brian Salvatore Safina

Stephen Allan Smith

Jonathan Mark Sutton

Hazel Joan Dyke

Deirdre Mary Bernadette Hickey

Sushant Malhotra

Jason Witherington

Craig Stivala

Ivan Leo Pinto

Terry Aaron Panchal

Binqing Wei

Frank Burkamp

Marian C Bryan

Colin O'Dowd

Matthew W Cartwright

James Samuel Shane Rountree

Hans Purkey

Bohdan Waszkowycz

Elsa Amandine Dechaux

Jamie Knight

Lixin Zhang

Graham Peter Trevitt

Jacqueline Carol Bloomer

Ramesh B Bambal

Mark Peter Bell

Sumita Bhattacharyya

Phillip Smith

Michael Steven Bodnarchuk

The invention relates to an indane compound according to Formula (I), or a pharmaceutically acceptable salt thereof, wherein R, R, R, R, R, R, L, n and p are as defined herein. The compounds are useful for treating antibacterial infection either as stand-alone antibiotics, or in combination with further antibiotics.

Indane derivatives for use in the treatment of bacterial infection

Spirocyclic 2,3-dihydro-7-azaindole compounds of formula (I): variations thereof, and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the spirocyclic 2,3-dihydro-7-azaindole compounds.

Spirocyclic 2,3-dihydro-7-azaindole compounds and uses thereof

Described herein are benzoxazepin oxazolidinone compounds with phosphoinositide-3 kinase (PI3K) modulation activity or function having the Formula I structure:

Benzoxazepin oxazolidinone compounds and methods of use

The invention relates to a compound which is an indane derivative according to Formula (I), or a pharmaceutically acceptable salt thereof, [FORMULA (I)] wherein R, R, R, n, R, p, q, L, X and m are as defined herein. The compounds are useful in the treatment of antibacterial infection either as stand alone antibiotics, or in combination with further antibiotics. The compounds can also be used in vitro, for example in cleaning compositions. 

Chemical compounds as antibiotics

Described herein are benzoxazepin oxazolidinone compounds with phosphoinositide-3 kinase (PI3K) modulation activity or function having the Formula I structure: 

This invention relates to novel compounds which are inhibitors of T790M containing EGFR mutants, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the prevention or treatment of cancer.

Aminopyrimidine compounds as inhibitors of T790M containing EGFR mutants

Benzoxazepin Formula I compounds, including stereoisomers, geometric isomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting the delta isoform of PI3K, and for treating disorders mediated by lipid kinases such as inflammation, immunological disorders, and cancer. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. 

Benzoxazepin compounds selective for PI3K P110 delta and methods of use

The invention relates to a series of compounds with particular activity as inhibitors of the serine-threonine kinase AKT. Also provided are pharmaceutical compositions comprising same as well as methods for treating cancer.

Pharmaceutical compounds

The present invention relates to novel pyridone derivatives capable of inhibiting &#x3b1;integrin mediated cell adhesion, processes for their preparation, compositions comprising them and their use in the treatment of diseases capable of being modulated by the inhibition of cell adhesion.

Growing community of inventors

Harlow, United Kingdom

Richard Leonard Elliott